156 related articles for article (PubMed ID: 22551811)
1. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection.
Pedersen GK; Madhun AS; Breakwell L; Hoschler K; Sjursen H; Pathirana RD; Goudsmit J; Cox RJ
J Infect Dis; 2012 Jul; 206(2):158-66. PubMed ID: 22551811
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.
Cox RJ; Pedersen G; Madhun AS; Svindland S; Sævik M; Breakwell L; Hoschler K; Willemsen M; Campitelli L; Nøstbakken JK; Weverling GJ; Klap J; McCullough KC; Zambon M; Kompier R; Sjursen H
Vaccine; 2011 Oct; 29(45):8049-59. PubMed ID: 21864624
[TBL] [Abstract][Full Text] [Related]
4. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
5. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
6. Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man.
Pedersen GK; Sjursen H; Nøstbakken JK; Jul-Larsen Å; Hoschler K; Cox RJ
Hum Vaccin Immunother; 2014; 10(8):2408-16. PubMed ID: 25424948
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
8. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
10. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
15. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
16. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.
Pedersen G; Major D; Roseby S; Wood J; Madhun AS; Cox RJ
Influenza Other Respir Viruses; 2011 Nov; 5(6):426-37. PubMed ID: 21668670
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
18. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
[TBL] [Abstract][Full Text] [Related]
20. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
